Genfit, Lille/ France
Genfit, an innovative biopharmaceutical company, is taking a multi-pronged approach in developing treatments to address unmet medical needs in Cardiometabolic and CNS disorders, such as, type 2 diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimerís. By focusing on early diagnosis, preventive solutions and therapeutic treatments, Genfit seeks to improve the quality of patientís lives. This approach is generating a strong portfolio of therapeutic products, tools, and clinical biomarkers.
In the joint project "OLNORME: Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites" Genfit and Bicoll combine their strength in biopharmaceutical drug discovery and development to search for novel ligands binding to a well-characterized class of nuclear receptors that are relevant targets for diseases with an inflammatory component but currently still lack any ligands. "OLNORME" bases on the screening of the highly diversified library of plant metabolites established by the Bicoll Group.
Ricerca Biosciences LLC, Concord/ USA
Ricerca Biosciences, LLC, located on a 46-acre site in Concord, Ohio, offers a unique IP-IND concept to pharmaceutical and biotechnology companies. Ricerca encompasses all discovery and development services required to bring intellectual property, in the form of a target or drug candidate, to a complete IND submission. The company performs both chemistry and biology services, as well as report writing and regulatory services and supports clinical trials through GMP API manufacture and bioanalytical services.
Joining forces, Bicoll and Ricerca combine their strengths in MedChem Services to offer innovative solutions that streamline drug discovery and development. With Ricercaís network of business development representatives throughout the United States, Bicoll is able to secure a close interaction to North American clients.
University of Freiburg, Department of Virology, Germany
Bicoll is cooperating with the group of Professor Georg Bauer at the department of virology, university of Freiburg/ Germany. An early research project has been started to understand the underlying mechanism of apoptosis. Bicoll was providing selected compounds of its small molecule natural product library BILOBAC N. After initial cooperation, the findings led to a common patent. Subsequently, Bicoll and Professor Bauer's group are participating in a major project cooperation including two more cooperation partners.